{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Langerhans-Cell+Histiocytosis&page=4",
    "query": {
      "condition": "Langerhans-Cell Histiocytosis",
      "page": 4
    },
    "page_size": 10
  },
  "pagination": {
    "page": 4,
    "page_size": 10,
    "total_count": 140,
    "total_pages": 14,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Langerhans-Cell+Histiocytosis&page=5&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Langerhans-Cell+Histiocytosis&page=3&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-10T20:27:53.074Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05642221",
      "title": "Functional Near-Infrared Spectroscopy (fNIRS) Combined With Diffuse Correlation Spectroscopy (DCS) in Neurocognitive Disease as Compared to Healthy Neurotypical Controls",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Juvenile Neuronal Ceroid Lipofuscinosis",
        "Smith-Lemli-Opitz Syndrome",
        "Creatine Transporter Deficiency",
        "Niemann-Pick Disease Type C1"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "110 Years",
        "sex": "ALL",
        "summary": "6 Months to 110 Years"
      },
      "enrollment_count": 73,
      "start_date": "2023-01-23",
      "completion_date": "2025-04-25",
      "has_results": false,
      "last_update_posted_date": "2026-10-08",
      "last_synced_at": "2026-10-10T20:27:53.074Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05642221"
    },
    {
      "nct_id": "NCT02254863",
      "title": "UCB Transplant of Inherited Metabolic Diseases With Administration of Intrathecal UCB Derived Oligodendrocyte-Like Cells",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Adrenoleukodystrophy",
        "Batten Disease",
        "Mucopolysaccharidosis II",
        "Leukodystrophy, Globoid Cell",
        "Leukodystrophy, Metachromatic",
        "Neimann Pick Disease",
        "Pelizaeus-Merzbacher Disease",
        "Sandhoff Disease",
        "Tay-Sachs Disease",
        "Brain Diseases, Metabolic, Inborn",
        "Alpha-Mannosidosis",
        "Sanfilippo Mucopolysaccharidoses"
      ],
      "interventions": [
        {
          "name": "DUOC-01",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Joanne Kurtzberg, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Week",
        "maximum_age": "22 Years",
        "sex": "ALL",
        "summary": "1 Week to 22 Years"
      },
      "enrollment_count": 40,
      "start_date": "2014-09",
      "completion_date": "2027-10",
      "has_results": false,
      "last_update_posted_date": "2026-09-03",
      "last_synced_at": "2026-10-10T20:27:53.074Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02254863"
    },
    {
      "nct_id": "NCT01372228",
      "title": "Phase I/II Pilot Study of Mixed Chimerism to Treat Inherited Metabolic Disorders",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Hurler Syndrome (MPS I)",
        "Hurler-Scheie Syndrome",
        "Hunter Syndrome (MPS II)",
        "Sanfilippo Syndrome (MPS III)",
        "Krabbe Disease (Globoid Leukodystrophy)",
        "Metachromatic Leukodystrophy (MLD)",
        "Adrenoleukodystrophy (ALD and AMN)",
        "Sandhoff Disease",
        "Tay Sachs Disease",
        "Pelizaeus Merzbacher (PMD)",
        "Niemann-Pick Disease",
        "Alpha-mannosidosis"
      ],
      "interventions": [
        {
          "name": "hematopoietic stem cell infusion",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Talaris Therapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 3,
      "start_date": "2011-04",
      "completion_date": "2016-04",
      "has_results": false,
      "last_update_posted_date": "2023-04-12",
      "last_synced_at": "2026-10-10T20:27:53.074Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01372228"
    },
    {
      "nct_id": "NCT03311854",
      "title": "A Study to Investigate the Safety and Efficacy of Emapalumab, an Anti-IFN-gamma mAb in Patients With Systemic Juvenile Idiopathic Arthritis (sJIA) or Adult-onset Still's Disease (AOSD) Developing Macrophage Activation Syndrome/Secondary HLH (MAS/sHLH)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Macrophage Activation Syndrome",
        "Lymphohistiocytosis, Hemophagocytic",
        "Arthritis, Juvenile",
        "Adult Onset Still Disease"
      ],
      "interventions": [
        {
          "name": "Emapalumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Swedish Orphan Biovitrum",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "0 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2018-02-20",
      "completion_date": "2020-05-19",
      "has_results": true,
      "last_update_posted_date": "2022-05-17",
      "last_synced_at": "2026-10-10T20:27:53.074Z",
      "location_count": 1,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03311854"
    },
    {
      "nct_id": "NCT00176826",
      "title": "T-Cell Depletion and Stem Cell Transplant for Immune Deficiencies and Histiocytic Disorders",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Hemophagocytic Lymphohistiocytosis",
        "X-Linked Lymphoproliferative Disorders",
        "Chediak-Higashi Syndrome",
        "Griscelli Syndrome",
        "Immunologic Diseases",
        "Langerhans-Cell Histiocytosis",
        "Hematologic Diseases"
      ],
      "interventions": [
        {
          "name": "Stem Cell Transplant",
          "type": "PROCEDURE"
        },
        {
          "name": "Myeloablative conditioning regimen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "Masonic Cancer Center, University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "Up to 55 Years"
      },
      "enrollment_count": 22,
      "start_date": "2000-09",
      "completion_date": "2015-08",
      "has_results": true,
      "last_update_posted_date": "2018-01-23",
      "last_synced_at": "2026-10-10T20:27:53.074Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00176826"
    },
    {
      "nct_id": "NCT04528355",
      "title": "Data Collection Study of Patients With Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT With RIC",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Primary Immunodeficiency (PID)",
        "Congenital Bone Marrow Failure Syndromes",
        "Inherited Metabolic Disorders (IMD)",
        "Hereditary Anemias",
        "Inflammatory Conditions"
      ],
      "interventions": [
        {
          "name": "data collection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Paul Szabolcs",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Months",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "2 Months to 60 Years"
      },
      "enrollment_count": 50,
      "start_date": "2020-08-20",
      "completion_date": "2028-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-01-13",
      "last_synced_at": "2026-10-10T20:27:53.074Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04528355"
    },
    {
      "nct_id": "NCT02292654",
      "title": "Safety, Tolerability, PK, and Efficacy Evaluation of Repeat Ascending Doses of Olipudase Alfa in Pediatric Patients <18 Years of Age With Acid Sphingomyelinase Deficiency",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Sphingomyelin Lipidosis"
      ],
      "interventions": [
        {
          "name": "Olipudase alfa",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genzyme, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "Up to 17 Years"
      },
      "enrollment_count": 20,
      "start_date": "2015-05-01",
      "completion_date": "2019-12-09",
      "has_results": true,
      "last_update_posted_date": "2022-03-23",
      "last_synced_at": "2026-10-10T20:27:53.074Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02292654"
    },
    {
      "nct_id": "NCT04551131",
      "title": "Use Of A Response-Adapted Ruxolitinib-Containing Regimen For The Treatment Of Hemophagocytic Lymphohistiocytosis",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Hemophagocytic Lymphohistiocytosis"
      ],
      "interventions": [
        {
          "name": "Ruxolitinib",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "St. Jude Children's Research Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Weeks",
        "maximum_age": "22 Years",
        "sex": "ALL",
        "summary": "6 Weeks to 22 Years"
      },
      "enrollment_count": 10,
      "start_date": "2021-07-13",
      "completion_date": "2026-08",
      "has_results": false,
      "last_update_posted_date": "2026-04-24",
      "last_synced_at": "2026-10-10T20:27:53.074Z",
      "location_count": 13,
      "location_summary": "Phoenix, Arizona • Orange, California • San Francisco, California + 10 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04551131"
    },
    {
      "nct_id": "NCT02281760",
      "title": "Dabrafenib and Trametinib in People With BRAF V600E Mutation Positive Lesions in Erdheim Chester Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "BRAF V600E Mutation"
      ],
      "interventions": [
        {
          "name": "Dabrafenib Mesylate",
          "type": "DRUG"
        },
        {
          "name": "Trametinib Dimethyl Sulfoxide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Human Genome Research Institute (NHGRI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 9,
      "start_date": "2014-11-01",
      "completion_date": "2018-08-29",
      "has_results": true,
      "last_update_posted_date": "2021-08-31",
      "last_synced_at": "2026-10-10T20:27:53.074Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02281760"
    },
    {
      "nct_id": "NCT07660783",
      "title": "Naive T Cell Deplete Grafts for GVHD Prevention in Non-Malignant Diseases",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Bone Marrow Failure",
        "Hemoglobinopathies",
        "Primary Immune Deficiency (PID)",
        "Autoimmune Cytopenia",
        "Immune Dysregulation",
        "Hemophagocytic Lymphohistiocytosis (HLH)",
        "Non Malignant Disorders"
      ],
      "interventions": [
        {
          "name": "ALLOGENEIC CD34+ ENRICHED AND CD45RA- DEPLETED PBSCs",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "6 Months to 50 Years"
      },
      "enrollment_count": 40,
      "start_date": "2026-09",
      "completion_date": "2035-09",
      "has_results": false,
      "last_update_posted_date": "2026-06-22",
      "last_synced_at": "2026-10-10T20:27:53.074Z",
      "location_count": 2,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07660783"
    }
  ]
}